PDS Biotech is a clinical-stage immunotherapy company developing cancer treatments with no approved products and no revenue. The company's pipeline is built on two proprietary platforms: Versamune, a lipid nanoparticle technology designed to generate tumor-specific CD8 killer T cells by mimicking viral uptake by dendritic cells, and PDS01ADC, an antibody-drug conjugate that delivers IL-12 (a T cell activator) directly into the tumor microenvironment to avoid the systemic toxicity historically associated with IL-12 therapy. PDS Biotech's lead program, PDS0101, combines Versamune with HPV16 antigens and is being evaluated primarily in HPV16-positive recurrent/metastatic head and neck cancer. The company initiated a Phase 3 registrational trial, VERSATILE-003, in March 2025, testing PDS0101 plus Merck's pembrolizumab versus pembrolizumab alone. PDS Biotech funds itself entirely through equity and debt financing, and by its own admission does not have sufficient capital to complete the Phase 3 trial, intending to raise funds in stages tied to clinical milestones. A notable feature of its model is reliance on investigator-initiated trials run by the NCI, MD Anderson, and Mayo Clinic, which allows PDS Biotech to generate data across multiple cancer types and combination strategies while directing its own capital toward VERSATILE-003. PDS Biotech holds an exclusive worldwide license to PDS01ADC from Merck KGaA. The company's longer-term strategy is to first win approval for PDS0101 plus pembrolizumab, then layer in PDS01ADC to create a triple combination, and expand into other HPV-related cancers and tumor antigens.